Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-15. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Lipoprotein(a) is a low-density lipoprotein variant containing a protein called apolipoprotein(a). Genetic and epidemiological studies have identified lipoprotein(a) as a risk factor for atherosclerosis and related diseases, such as coronary heart disease and stroke. Lipoprotein(a) was discovered in 1963 by Kåre Berg. The human gene encoding apolipoprotein(a) was successfully cloned in 1987.
==== Stepwise coupling and coding ==== One of the most forward-looking method commonly used for DNA-encoding is applied in the synthesis of single-pharmacophore libraries. As the figure shows the library is built repeating the usual cycles of S&P synthesis, The second operation of the cycle is modified: in addition to coupling with the BBs the encoding DNA oligomer is elongated by attaching the code of the BB by ligation.
Additionally, warthog tusks, and teeth from sperm whales, orcas and hippos can also be scrimshawed or superficially carved, thus retaining their morphologically recognizable shapes. As trade with Africa expanded during the first part of the 1800s, ivory became readily available. Up to 90 percent of the ivory imported into the United States was processed, at one time, in Connecticut where Deep River and Ivoryton in 1860s became the centers of ivory milling, in particular, due to the demand for ivory piano keys.
Sources: en.wikipedia.org
CaMKII has multiple modes of activation to cause the incorporation of AMPA receptors into the perisynaptic membrane. CAMKII enzyme is eventually responsible for the development of the actin cytoskeleton of neuronal cells and, eventually, for the dendrite and axon development (synaptic plasticity). The first is direct phosphorylation of synaptic-associated protein 97 (SAP97), a scaffolding protein. First, SAP-97 and Myosin-VI, a motor protein, are bound as a complex to the C-terminus of AMPARs. Following phosphorylation by CaMKII, the complex moves into the perisynaptic membrane. The second mode of activation is through the MAPK pathway. CaMKII activates the Ras proteins, which go on to activate p42/44 MAPK, which drives AMPAR insertion directly into the perisynaptic membrane.
ASTM D482: Standard Test Method for Ash from Petroleum Products; ISO 6245: Petroleum products — Determination of ash; ASTM D874: Standard Test Method for Sulfated Ash from Lubricating Oils and Additives; ASTM D3174: Standard Test Method for Ash in the Analysis Sample of Coal and Coke from Coal; ISO 1171: Solid mineral fuels — Determination of ash; ISO 18122: Solid biofuels — Determination of ash content; ASTM D1102: Standard Test Method for Ash in Wood; ASTM D2974: Standard Test Methods for Determining the Water (Moisture) Content, Ash Content, and Organic Material of Peat and Other Organic Soils; ASTM D2866: Standard Test Method for Total Ash Content of Activated Carbon; ISO 3451: Plastics — Determination of ash — Part 1: General methods; ASTM D2584: Standard Test Method for Ignition Loss of Cured Reinforced Resins; and ASTM D5630: Standard Test Method for Ash Content in Plastics.
== Personal life == Growing up in Mildura, he supported the Essendon Football Club, and his hero was Matthew Lloyd. In 2009, Steinberg played gridiron in Alberta, Canada whilst on student exchange. In Canada, Steinberg was the punter for his high school, the McNally Tigers, and he also played regular Aussie Rules games for the Edmonton men's side and helped coach and umpire for the Emus women's team. Women's Australian rules Football in Edmonton now rapidly growing supplying half the women for the Canadian National team. He has two sisters, Hadassah and Yael, and brother Asher.
===== Pharmacodynamics ===== This class of drugs initially stimulates the anterior pituitary gland to secrete more GnRH, leading to a temporary surge in GnRH level in the circulation. Yet, because of the desensitization effect on the receptors upon continuous stimulation, in the long term, its secretion will be inhibited if continual medication is prescribed. Particularly, GnRH is essential for the release of gonadotropic hormones, such as LH and follicle-stimulating hormone (FSH), from the anterior pituitary-body. These hormones are responsible for the synthesis of steroid sex hormones (testosterone in men; progesterone and estrogen in women). Therefore, GnRH inhibition by these drugs, in turn, reduces the secretion of steroid sex hormones from the sex organs, eventually leading to libido suppression.
Sources: en.wikipedia.org
Consequently, independent homeowners inhibited the construction of New Deal sponsored public housing by using civic disorder and rioting as political tools to consolidate homeowner rejection of black occupancy in middle-class neighborhoods. Consequently, the political dominance white homeowners assumed in Detroit's housing disputes encouraged the Detroit Housing Commission (DHC) to establish racist policies, such as the continuation of racial segregation within Detroit's housing market, allowing the DHC to avoid the racial bloodshed of public housing construction. Additionally, New Deal policy promoted the formation of private-public partnerships to manage the allocation of federal funds within local municipalities. These private-public partnerships established residential segregation through a tactic called redlining, which restricted the movement of black Detroiters into middle-class neighborhoods. In particular, the Federal Housing Administration (FHA) and the Home Owners Loan Corporation (HOLC) effectively marked the racial boundaries of Detroit to determine the actuarial soundness of urban neighborhoods. Therefore, redlining governed the dispersal of federal loans and subsidies on the basis of the racial composition of a neighborhood. Local real estate brokers and lenders refused to allocate federal funds to predominantly black communities such as Paradise Valley along with neighborhoods that had only a handful of black residents as these areas were all categorized as unfit and hazardous investments for mortgages.
== See also == Barbro Hjalmarsson Biomarker (medicine), a protein or other biomolecule measured in a blood test Blood film, a way to look at blood cells under a microscope Blood gas test Blood lead level Hematology – Study of blood and blood diseases Luminol, a visual test for blood left at crime scenes. Reference ranges for blood tests Schumm test – Test for blood mismatch Category:Blood tests List of medical tests
where Pb, Th and U are concentrations in parts-per-million, and λ232, λ235 and λ238 are the decay constants of 232Th, 235U and 238U respectively. For chemical dating results to be valid, the following assumptions are required:
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.